Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3889207 | 0.91 | ALDH1A1 (0.41) | KCNH2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL12349963 | 0.87 | BRAF (0.38) | KCNH2MEN1KMT2ALMNABRAF | |
| SCHEMBL3887751 | 0.86 | KCNH2 (0.42) | KCNH2MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2193376 | 0.85 | BRAF (0.47) | KCNH2BRAFRIPK2NR1I2EGFR | |
| SCHEMBL12507996 | 0.85 | KCNH2 (0.42) | KCNH2MEN1KMT2ALMNABRAF | |
| SCHEMBL2194702 | 0.84 | BRAF (0.46) | KCNH2BRAFRIPK2NR1I2EGFR | |
| SCHEMBL12508284 | 0.84 | KCNH2 (0.42) | KCNH2BRAFRIPK2NR1I2SMN1; SMN2 | |
| SCHEMBL3884105 | 0.84 | NR1I2 (0.47) | BRAFNR1I2EGFR | |
| SCHEMBL2194335 | 0.84 | BRAF (0.59) | BRAFRIPK2NR1I2 | |
| SCHEMBL1127145 | 0.83 | KCNH2 (0.44) | KCNH2BRAFRIPK2NR1I2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-2282636-B1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | NOVARTIS AG (CH) | 2016-03-23 | — | — | EP | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8642759-B2 | Benzene sulfonamide thiazole and oxazole compounds | GLAXOSMITHKLINE LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-8415345-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo SmithKline LLC (US) | 2013-04-09 | — | — | US | disclosed |
| EP-2498608-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | GlaxoSmithKline LLC (US) | 2012-09-19 | — | — | EP | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885MEN1 3639/4885KMT2A 2622/4885 |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885MEN1 3639/4885KMT2A 2622/4885 |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885MEN1 3639/4885KMT2A 2622/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | KCNH2 1701/4885MEN1 3639/4885KMT2A 2622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.